Answers are grounded in this paper and cite their sources.
Lysosomal storage disorders (LSDs) are a heterogeneous group of inherited diseases, caused primarily by a deficiency of an enzyme responsible for the catabolism of various substrates; by-products of cellular turnover. As a consequence, there is progressive accumulation of incompletely metabolized materials in different cell types; and the corresponding tissues involved define the pattern of disease expression. The LSDs have been traditionally classified according to the biochemical composition of tissue deposits (e.g., glycosphingolipids and glycosaminoglycans). More recently, delineation of disease mechanisms has prompted grouping on the basis of the functional defect (e.g., enzyme deficiency or intracellular transport problem). Prior to the advent of enzyme-replacement therapy, management options were mainly palliative; although bone marrow transplantation was, and remains, a therapeutic approach for selected disorders. This review will examine the use of enzyme-replacement therapy and substrate-reduction therapy for particular LSD subtypes, and also briefly discuss emerging approaches that are currently in clinical trials (i.e., chaperone-mediated enzyme enhancement and stem cell and gene therapy).
No takes yet. Share an insight, caveat, or question.
Gregory M. Pastores (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: